Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population


TÜREDİ S., Cinar O., Yavuz I., MENTEŞE A., GÜNDÜZ A., KARAHAN S. C. , ...More

JOURNAL OF NEPHROLOGY, vol.23, no.3, pp.335-340, 2010 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 3
  • Publication Date: 2010
  • Journal Name: JOURNAL OF NEPHROLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.335-340
  • Keywords: End stage renal disease, Ischemia-modified albumin, Hemodialysis, Renal failure, HEMODIALYSIS-PATIENTS, MYOCARDIAL-ISCHEMIA, PULMONARY-EMBOLISM, DIALYSIS MEMBRANE, MARKER, DIAGNOSIS

Abstract

Introduction: Conventional biomarkers suffer from the drawback of being elevated in chronic renal failure even in the absence of myocardial ischemia. Ischemia-modified albumin (IMA) is a new biomarker proposed for the diagnosis of myocardial ischemia. This study was performed with the primary aim of determining IMA levels in patients with end stage renal disease (ESRD). The secondary aim of the study was to determine the impact of hemodialysis (HD), HD speed, and hemoglobin (Hb) levels on IMA levels.